Search
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalOsimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. … [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, P-glycoprotein substratesCT-011
go.drugbank.com/drugs/DB05916InvestigationalIt is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Bifonazole
go.drugbank.com/drugs/DB04794ApprovedBifonazole is an azole antifungal drug.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseSynonyms: (+-)-1-(p,alpha-Diphenylbenzyl)imidazole, 1-(p,alpha-Diphenylbenzyl)imidazolePrussian blue
go.drugbank.com/drugs/DB06783ApprovedIt is orally administered for clinical purposes to be used as an antidote for certain kinds of heavy metal poisoning, such as thallium and radioactive isotopes of caesium. … It is insoluble in water but also tends to form a colloid thus can exist in either colloidal or water-soluble form, and an insoluble form.
Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationalIn early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for … [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy
Categories: Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors, P-glycoprotein inhibitorsPentoxyverine
go.drugbank.com/drugs/DB11186ApprovedWithdrawnIt is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists [A32160].
Mixtures: Corzall PEBexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigationalIts use is not recommended in patients with type 1 diabetes since it may increase their risk of diabetic ketoacidosis.[L44758] … [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesVilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone may also be associated with less sexual dysfunction and weight gain[A6947]. Vilazodone was given FDA approval on January 21, 2011[L6046,A177622]. … Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622].
Categories: Antidepressive Agents Indicated for Depression, Cytochrome P-450 Substrates